GT Biopharma, Inc. Uncategorized Contracts & Agreements
20 Contracts & Agreements
- Investigator Initiated Clinical Trial Agreement, dated as of November 18, 2024, by and between GT Biopharma, Inc. and the Regents of the University of Minnesota (Filed With SEC on November 21, 2024)
- Sponsored Research Agreement with the Regents of the University of Minnesota dated May 20, 2024 (Filed With SEC on August 14, 2024)
- Description of the Registrants Securities Registered pursuant to Section 12 of the Securities Exchange Act of 1934, as Amended (Filed With SEC on March 30, 2023)
- Research Agreement with Regents of the University of Minnesota, dated June 16, 2021 (Filed With SEC on March 28, 2022)
- SETTLEMENTAGREEMENT (Filed With SEC on December 28, 2020)
- Consultant Agreement with Michael Handelman, dated November 13, 2020 (Filed With SEC on November 13, 2020)
- Steve Weldon Letter of Resignation, dated November 11, 2020 (Filed With SEC on November 13, 2020)
- Clinical Trial Agreement with University of Minnesota (Filed With SEC on May 15, 2020)
- Consultant Agreement, dated as of February 14, 2018, between the Company and Mr. Cataldo (Filed With SEC on February 21, 2018)
- Amended Preferred Conversion Agreement (Filed With SEC on November 14, 2017)
- Preferred Conversion Agreement (Filed With SEC on November 14, 2017)
- EMPLOYMENTAGREEMENT (Filed With SEC on November 14, 2017)
- RESEARCH AGREEMENT (Filed With SEC on March 13, 2015)
- [OXIS LETTERHEAD] (Filed With SEC on October 9, 2009)
- SECURED PROMISSORYNOTE (Filed With SEC on December 18, 2008)
- ASSETPURCHASE AGREEMENT (Filed With SEC on December 18, 2008)
- AGREEMENT (Filed With SEC on December 10, 2008)
- BRISTOL CAPITAL ADVISORS, LLC (Filed With SEC on June 24, 2008)
- BRISTOLCAPITAL ADVISORS, LLC (Filed With SEC on June 13, 2008)
- Exhibit 10.1 (Filed With SEC on March 4, 2005)
